Overall survival | Recurrence free survival | |||||
---|---|---|---|---|---|---|
Variables | HR | 95% CI | p value | HR | 95% CI | p value |
Age at surgery 1, a | 1.27 | 0.84–1.91 | 0.255 | 1.00 | 0.67–1.48 | 0.982 |
Lymph node ratio | 0.007 b,* | 1.02 | 0.020 b,* | |||
Within High 53BP1 level strata 2, a | 0.98 | 0.43–2.22 | 0.958 | 3.92 | 0.45–2.29 | 0.963 |
Within Low 53BP1 level strata 2, a | 4.84 | 2.26–10.37 | <0.001* | 1.79–8.58 | <0.001* | |
CA19-9 | 0.040 b,* | 0.226 b | ||||
Within High 53BP1 level strata 3, a | 0.87 | 0.52–1.47 | 0.606 | 0.94 | 0.56–1.57 | 0.803 |
Within Low 53BP1 level strata 3, a | 1.72 | 1.18–2.51 | 0.005* | 1.38 | 0.97–1.96 | 0.077 |
Adjuvant chemotherapy: Yes | 0.34 | 0.19–0.60 | <0.001* | 0.55 | 0.30–1.00 | 0.051 |
Margin Positive | 2.37 | 1.35–4.14 | 0.003* | 1.36 | 0.75–2.47 | 0.316 |
Peripancreatic extension status Positive | 2.29 | 1.12–4.65 | 0.022* | 2.41 | 1.16–5.01 | 0.019* |
Perineural invasion status Positive | 0.52 | 0.29–0.95 | 0.033* | 0.46 | 0.25–0.81 | 0.008* |